<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TESTOSTERONE CYPIONATE- testosterone cypionateÂ injection, solutionÂ </strong><br>A-S Medication Solutions LLC<br></p></div>
<h1>
<span class="Bold">TESTOSTERONE CYPIONATE INJECTION USP CIII<br></span><span class="Bold">FOR INTRAMUSCULAR USE ONLY<br><br></span><span class="Bold">Rx only</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION:</span></h1>
<p class="First">Testosterone Cypionate Injection for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone.</p>
<p>Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils.</p>
<p>The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1-oxopropoxy)-, (17Î²)-. Its molecular formula is C<span class="Sub">27</span>H<span class="Sub">40</span>O<span class="Sub">3</span> and the molecular weight 412.61.<br>The structural formula is represented below:</p>
<div class="Figure"><img alt="Testosterone Cypionate Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=786cfd08-40a2-420a-bb29-230db15816bc&amp;name=testosterone-cypionate-injection-1.jpg"></div>
<p>Each mL contains: Testosterone Cypionate 200 mg, Benzyl Benzoate 20%, with Benzyl Alcohol 0.9% as preservative in Cottonseed Oil q.s.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY:</span></h1>
<p class="First">Endogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of prostate, seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest and axillary hair; laryngeal enlargement, vocal chord thickening, and alterations in body musculature and fat distribution. Drugs in this class also cause retention of nitrogen, sodium, potassium, and phosphorus, and decreased urinary excretion of calcium. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are responsible for the growth spurt of adolescence and for eventual termination of linear growth, brought about by fusion of the epiphyseal growth centers. In children, exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> accelerate linear growth rates, but may cause disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of the growth process. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to stimulate production of red blood cells by enhancing production of erythropoietic stimulation factor.</p>
<p>During exogenous administration of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).</p>
<p>There is a lack of substantial evidence that <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are effective in <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, surgery, convalescence, and functional <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.1"></a><p></p>
<h2><span class="Bold">Pharmacokinetics:</span></h2>
<p class="First">Testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus, testosterone cypionate can be given at intervals of two to four weeks.</p>
<p>Testosterone in plasma is 98 percent bound to a specific testosterone-estradiol binding globulin, and about 2 percent is free. Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine its half-life.</p>
<p>About 90 percent of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6 percent of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver. Testosterone is metabolized to various 17-keto steroids through two different pathways.</p>
<p>The half-life of testosterone cypionate when injected intramuscularly is approximately eight days.</p>
<p>In many tissues the activity of testosterone appears to depend on reduction to dihydrotestosterone, which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where it initiates transcription events and cellular changes related to androgen action.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE:</span></h1>
<p class="First">Testosterone Cypionate Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone.</p>
<ol class="Arabic">
<li><p class="First">Primary <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> (congenital or acquired)-testicular failure due to <span class="product-label-link" type="condition" conceptid="437655" conceptname="Undescended testicle">cryptorchidism</span>, bilateral torsion, <span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span>, vanishing testis syndrome; or orchidectomy.</p></li>
<li><p class="First">Hypogonadotropic <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> (congenital or acquired)-idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or radiation.</p></li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS:</span></h1>
<ol class="Arabic">
<li><p class="First">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug</p></li>
<li><p class="First">Males with carcinoma of the breast</p></li>
<li><p class="First">Males with known or suspected carcinoma of the prostate gland</p></li>
<li><p class="First">Women who are or who may become pregnant</p></li>
<li><p class="First">Patients with serious cardiac, hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span></p></li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS:</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> may occur in immobilized patients. If this occurs, the drug should be discontinued.</p>
<p>Prolonged use of high doses of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> (principally the 17-Î± alkyl-<span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>) has been associated with development of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span>, hepatocellular carcinoma, and <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> â€“ all potentially life-threatening complications.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk of developing <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma although conclusive evidence to support this concept is lacking.</p>
<p>There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (VTE) in men taking testosterone, including testosterone cypionate. Testosterone use may increase the risk of VTE, including <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) and acute <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE). Consider VTE in patients who report symptoms of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, warmth and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> in the leg (DVT) or acute <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> (PE). In such patients, discontinue treatment with testosterone cypionate and evaluate patients for possible VTE.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, with or without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, may be a serious complication in patients with pre-existing cardiac, renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> may develop and occasionally persists in patients being treated for <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>.</p>
<p>This product contains benzyl alcohol. Benzyl alcohol has been reported to be associated with a fatal â€œGasping Syndromeâ€? in premature infants.</p>
<p>Androgen therapy should be used cautiously in healthy males with <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every 6 months. In children, androgen treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height.</p>
<p>This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS:</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2><span class="Bold">General:</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hypertrophy</span> may develop acute <span class="product-label-link" type="condition" conceptid="4318847" conceptname="Obstruction of urethra">urethral obstruction</span>. <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> or excessive sexual stimulation may develop. <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> may occur after prolonged administration of excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized.</p>
<p>Testosterone cypionate should not be used interchangeably with testosterone propionate because of differences in duration of action.</p>
<p>Testosterone cypionate <span class="Italics">is notÂ </span>for intravenous use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold">Information for Patients:</span></h2>
<p class="First">Patients should be instructed to report any of the following: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, changes in skin color, <span class="product-label-link" type="condition" conceptid="4144411" conceptname="Swollen ankle">ankle swelling</span>, too frequent or persistent erections of the penis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2><span class="Bold">Laboratory Tests:</span></h2>
<p class="First">Hemoglobin and hematocrit levels (to detect <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>) should be checked periodically in patients receiving long-term androgen administration.<br>Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> may increase during androgen therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2><span class="Bold">Drug Interactions:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>.</p>
<p>Concurrent administration of oxyphenbutazone and <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may result in elevated serum levels of oxyphenbutazone.</p>
<p>In diabetic patients, the metabolic effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may decrease blood glucose and, therefore, insulin requirements.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2><span class="Bold">Drug/Laboratory Test Interferences:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may decrease levels of thyroxine-binding globulin, resulting in decreased total T<span class="Sub">4</span> serum levels and increased resin uptake of T<span class="Sub">3</span> and T<span class="Sub">4</span>. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6"></a><p></p>
<h2><span class="Bold">Carcinogenesis:</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6.1"></a><p></p>
<h3><span class="Bold">Animal Data:</span></h3>
<p class="First">Testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of female mice increases their susceptibility to <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span>. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically-induced carcinomas of the liver in rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6.2"></a><p></p>
<h3><span class="Bold">Human Data:</span></h3>
<p class="First">There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk of developing <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma although conclusive evidence to supportÂ  this concept is lacking.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7"></a><p></p>
<h2><span class="Bold">Pregnancy:</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7.1"></a><p></p>
<h3>Teratogenic Effects.</h3>
<p class="First">Pregnancy Category X (See <a href="#LINK_cc5484d4-3c16-4370-bf43-9cd90377bf5e">CONTRAINDICATIONS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.8"></a><p></p>
<h2><span class="Bold">Nursing Mothers:</span></h2>
<p class="First">Testosterone Cypionate Injection is not recommended for use in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.9"></a><p></p>
<h2><span class="Bold">Pediatric Use:</span></h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 12 years have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS:</span></h1>
<p class="First">The following adverse reactions in the male have occurred with some <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold">Endocrine and Urogenital:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> and excessive frequency and duration of penile erections. <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> may occur at high dosages.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold">Skin and Appendages:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span>, male pattern of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">baldness</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2><span class="Bold">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span>:</span></h2>
<p class="First">Retention of sodium, chloride, water, potassium, calcium, and <span class="product-label-link" type="condition" conceptid="4106483" conceptname="P">inorganic phosphates</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2><span class="Bold">Gastrointestinal:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, alterations in liver function tests, rarely hepatocellular neoplasms and <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> (See <a href="#LINK_497ebd8e-5236-43ac-a1f3-d7448dff031e">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2><span class="Bold">Hematologic:</span></h2>
<p class="First">Suppression of clotting factors II, V, VII, and X, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients on concomitant anticoagulant therapy, and <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2><span class="Bold">Allergic:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, including skin manifestations and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8"></a><p></p>
<h2><span class="Bold">Miscellaneous:</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the site of intramuscular injection.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>:</span></h1>
<p class="First">Controlled Substance Class: Testosterone is a controlled substance under the Anabolic Steroids Control Act, and Testosterone Cypionate Injection has been assigned to Schedule III.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE:</span></h1>
<p class="First">There have been no reports of acute overdosage with the <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION:</span></h1>
<p class="First">Testosterone Cypionate Injection is for intramuscular use only. It should not be given intravenously. Intramuscular injections should be given deep in the gluteal muscle.</p>
<p>The suggested dosage for Testosterone Cypionate Injection varies depending on the age, sex, and diagnosis of the individual patient. Dosage is adjusted according to the patientâ€™s response and the appearance of adverse reactions.</p>
<p>Various dosage regimens have been used to induce pubertal changes in hypogonadal males; some experts have advocated lower dosages initially, gradually increasing the dose as puberty progresses, with or without a decrease to maintenance levels. Other experts emphasize that higher dosages are needed to induce pubertal changes and lower dosages can be used for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose.</p>
<p>For replacement in the hypogonadal male, 50 to 400 mg should be administered every two to four weeks.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.Â  Warming and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> the vial should redissolve any crystals that may have formed during storage at temperatures lower than recommended.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_HOWSUPPLIED"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<table border="0" cellpadding="1" cellspacing="1">
<colgroup><col width="100%"></colgroup>
<tbody class="Headless">
<tr class="First Toprule"><td align="left" valign="bottom"><p class="First">Repackaged by A-S Medication Solutions - Libertyville, IL<br>See <span class="Bold Italics"><a href="#Repack">REPACKAGING INFORMATION</a></span> for available configurations.</p></td></tr>
<tr class="Last"><td align="left" valign="bottom"><img alt="A-S Medication Solutions" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=786cfd08-40a2-420a-bb29-230db15816bc&amp;name=ASMLogo.jpg"></td></tr>
</tbody>
</table>
<p class="First">Testosterone Cypionate Injection USP, 200 mg/mL is available in:</p>
<p>10 mL multiple dose vials, individually boxed Â Â Â Â Â Â Â Â Â Â  NDC 0591-3223-79</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p><span class="Bold">PROTECT FROM LIGHT.</span></p>
<p>Literature revised: April 2014</p>
<p>Manufactured by:<br><span class="Bold">Hikma Farmaceutica (Portugal) <br></span>S.A. 2705-906 Terrugem SNT, Portugal</p>
<p>Distributed by:<br><span class="Bold">Watson Pharma, Inc. <br></span>Parsippany, NJ 07054 USA. </p>
<p><span class="Bold">PIN230-WAT/3</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Repack"></a><a name="section-12"></a><p></p>
<h1>REPACKAGING INFORMATION</h1>
<p class="First">Please reference the <span class="Bold Italics"><a href="#LINK_HOWSUPPLIED">HOW SUPPLIED</a></span> section listed above for a description of individual tablets or capsules.  This drug product has been received by A-S Medication Solutions - Libertyville, IL in a manufacturer or distributor packaged configuration and repackaged in full compliance with all applicable cGMP regulations.  The package configurations available from A-S Medication Solutions are listed below:</p>
<table border="0" cellpadding="1" cellspacing="1" width="46%">
<colgroup>
<col width="18%">
<col width="10%">
<col width="18%">
</colgroup>
<tbody class="Headless">
<tr class="First Toprule">
<td class="Bold" align="center" valign="bottom">NDC#</td>
<td align="center" valign="bottom"><span class="Bold">Count</span></td>
<td align="center" valign="bottom"><span class="Bold">Strength</span></td>
</tr>
<tr class="Last">
<td align="center" valign="bottom">50090-0331-0</td>
<td align="center">10</td>
<td align="center">200 mg</td>
</tr>
</tbody>
</table>
<p>
                     Repackaged by:<br><img alt="A-S Medication Solutions" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=786cfd08-40a2-420a-bb29-230db15816bc&amp;name=ASMLogo.jpg"><br>Libertyville, IL 60048</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 50090-0331-0</span></p>
<p>Relabeled by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="50090-0331-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=786cfd08-40a2-420a-bb29-230db15816bc&amp;name=50090-0331-0.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TESTOSTERONE CYPIONATEÂ 		
					</strong><br><span class="contentTableReg">testosterone cypionate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50090-0331(NDC:0591-3223)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TESTOSTERONE CYPIONATE</strong> (TESTOSTERONE) </td>
<td class="formItem">TESTOSTERONE CYPIONATE</td>
<td class="formItem">200Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL BENZOATE</strong></td>
<td class="formItem">223.6Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">9.9Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COTTONSEED OIL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50090-0331-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA086030</td>
<td class="formItem">05/04/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>A-S Medication Solutions LLC
							(830016429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A-S Medication Solutions LLC</td>
<td class="formItem"></td>
<td class="formItem">830016429</td>
<td class="formItem">relabel(50090-0331)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5f49c205-cb3c-48b9-8e14-f1261b276062</div>
<div>Set id: 786cfd08-40a2-420a-bb29-230db15816bc</div>
<div>Version: 1</div>
<div>Effective Time: 20141215</div>
</div>
</div>Â <div class="DistributorName">A-S Medication Solutions LLC</div></p>
</body></html>
